Does holding at 12.5 mg for four weeks before escalating reduce constipation?

The case in front of me: 12.5 mg · four weeks · constipation.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Is the standard explanation correct, and if so, what is the evidence for it?

four weeks at 12.5 mg is 28 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 12.5 mg back by 28 days. Whether that reduces constipation depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 12.5 mg is 12.5 mg on day 1 and on day 28. A symptom driven by the rate of change has 28 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot constipation against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Put another way, the published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

The top of the schedule is not the target. The working dose is.

edited 20 Mar 2025 by Dr_Hanne_Solberg — added a caveat about sampling

Mechanically, this is the single most consequential controllable variable in the whole experience, and people routinely rush it.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

The relevant detail is that escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

Four half-lives between steps, minimum. Work it out for your agent.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

The underlying point is that titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Hold rather than escalate while symptoms are active. Always.

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Slower costs time and nothing else. The ceiling is the same.

The initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Stepping back is a normal adjustment, not a failure.